A Trial of TTI-621 for Patients With Hematologic Malignancies

Official Title

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies

Summary:

Multicentre, open-label, Phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies.

Trial Description

Primary Outcome:

  • Dose-limiting Toxicity (DLT)
This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies that will be conducted in 2 parts. In the dose Escalation Phase, subjects with lymphoma will be enrolled in sequential dose cohorts to receive TTI-621 to characterize safety, tolerability, pharmacokinetics, and the maximum-tolerated dose (MTD). In the Expansion Phase, subjects with a variety of hematologic malignancies will be treated at the optimal dose to further define safety and to characterize efficacy.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society